Ischemic stroke in cancer patients: A review of an underappreciated pathology

Currently 1 in 10 patients with ischemic stroke have comorbid cancer, and this frequency is expected to increase with continued advances in cancer therapeutics prolonging median survival. Well known for its association with venous thrombosis, cancer has recently emerged as a significant risk factor...

Full description

Saved in:
Bibliographic Details
Published inAnnals of neurology Vol. 83; no. 5; pp. 873 - 883
Main Authors Navi, Babak B., Iadecola, Costantino
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.05.2018
Subjects
Biomarkers
Cancer
Health risks
Ischemia
Medical prognosis
Patients
Risk factors
Stroke
Thromboembolism
Thrombosis
Online AccessGet full text

Cover

More Information
Summary:Currently 1 in 10 patients with ischemic stroke have comorbid cancer, and this frequency is expected to increase with continued advances in cancer therapeutics prolonging median survival. Well known for its association with venous thrombosis, cancer has recently emerged as a significant risk factor for arterial thromboembolism, including stroke; however, the underlying mechanisms are uncertain. In addition, the optimal strategies to prevent and acutely treat stroke in cancer patients are yet to be established. This review summarizes the current evidence on ischemic stroke risk, biomarkers, pathophysiology, treatments, and prognosis in cancer patients, emphasizing knowledge gaps and the potential strategies to address them. Ann Neurol 2018;83:873–883
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:0364-5134
1531-8249
DOI:10.1002/ana.25227